Key result
BM-MSCs and exosomes reduce isoproterenol-induced cardiomyopathy damage, with exosomes providing greater therapeutic benefit.
Why the study?
Bone marrow-derived mesenchymal stem cells (BM-MSCs) and their exosomes have potential to prevent heart injury, but their comparative healing effects on isoproterenol-induced cardiomyopathy required evaluation.
Do bone marrow-derived mesenchymal stem cells or their exosomes improve myocardial damage in a rat model of isoproterenol-induced cardiomyopathy?
Do bone marrow-derived mesenchymal stem cells or their exosomes improve myocardial damage in a rat model of isoproterenol-induced cardiomyopathy?
BM-MSCs and their exosomes significantly reduce degenerative changes in isoproterenol-induced cardiomyopathy in rats, with exosomes showing a more pronounced therapeutic effect.
May support BM-MSC/exosome therapy in experimental cardiomyopathy; leaves open translation to human MI.
Introduction: Myocardial infarction (MI) is among the more serious cardiovascular diseases (CVDs). Isoproterenol (ISO) mimics cardiac muscle damage by increasing heart activity. Treatment using bone marrow-derived mesenchymal stem cells (BM-MSCs) and their exosomes has been studied due to their potential beneficial impact in preventing heart injury from developing. Aim of Work: To assess and compare the healing effect of BM-MSCs versus their exosomes on ISO-induced cardiomyopathy in adult rats. Materials and Methods: The experiment involved 44 male albino rats, with 36 adult rats weighing between 200 and 250 grams. The remaining 8 albino rats, weighing between 100 and 120 grams, were employed to produce BM-MSCs and exosomes. The 36 adult rats were divided into 4 groups. Group I: control group. Group II (ISO group): Rats were injected subcutaneously with ISO at 5 mg/kg, once daily, 24 hrs apart, for 7 consecutive days. Group III (ISO + BM-MSC group): rats received injections through the tail veins once with 2,000,000 stem cells/ml after a final ISO dose. Group IV (ISO + Exosomes group): Rats obtained injections through the tail vein once at 100 μg of protein extract of BM-MSC-Exosomes following the final ISO dosage. After 3 weeks from the beginning of the experiment, all animals were killed to collect the heart specimens. Results: The ISO group revealed myocardial damage characterized by disarray and degeneration. Damaged myocytes had sarcoplasm that was extremely acidophilic. A notable rise in the CK-MB blood level, increased collagen deposition, and apoptosis were observed. The two groups treated with BM-MSCs and their exosomes demonstrated improvements in many tested parameters, including decreased collagen deposition and decreased necrosis and apoptosis. The exosome-treated group exhibited the most significant improvement. Conclusion: Administration of BM-MSCs and their exosomes significantly reduces degenerative changes in isoproterenol-induced cardiomyopathy, with exosomes displaying an even more pronounced therapeutic effect.
No takes yet. Share an insight, caveat, or question.
ahmed et al. (2026) studied Isoproterenol-induced cardiomyopathy (n=44). Bone marrow-derived mesenchymal stem cells (BM-MSCs) and their exosomes vs. Isoproterenol alone was evaluated on Myocardial damage, CK-MB levels, collagen deposition, and apoptosis. Administration of BM-MSCs and their exosomes reduced degenerative changes in isoproterenol-induced cardiomyopathy, with exosomes displaying a more pronounced therapeutic effect.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: